These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11924911)

  • 1. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
    Thurber SE; Khong HT; Kammula US; Rosenberg SA
    J Immunother; 2002; 25(1):63-71. PubMed ID: 11924911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
    Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
    Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
    J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
    Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
    Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.
    Terheyden P; Schrama D; Pedersen LØ; Andersen MH; Kämpgen E; thor Straten P; Becker JC
    Scand J Immunol; 2003 Nov; 58(5):566-71. PubMed ID: 14629628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
    Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
    Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
    Marincola FM; Rivoltini L; Salgaller ML; Player M; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):266-77. PubMed ID: 8877721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
    Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U
    Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.
    Kammula US; Marincola FM; Rosenberg SA
    J Natl Cancer Inst; 2000 Aug; 92(16):1336-44. PubMed ID: 10944556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
    Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
    J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.